RA CAPITAL MANAGEMENT, L.P. - 12 Feb 2024 Form 4 Insider Report for Mineralys Therapeutics, Inc. (MLYS)

Role
Director
Signature
/s/ Peter Kolchinsky, Manager of RA Capital Management, L.P.
Issuer symbol
MLYS
Transactions as of
12 Feb 2024
Net transactions value
+$30,000,001
Form type
4
Filing time
14 Feb 2024, 19:49:34 UTC
Previous filing
13 Feb 2024
Next filing
20 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MLYS Common Stock Award $22,578,858 +1,672,508 +128% $13.50 2,983,755 12 Feb 2024 See footnote F1, F2
holding MLYS Common Stock 1,867,229 12 Feb 2024 See Footnote F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MLYS Pre-Funded Warrants (Right to Buy) Award $7,421,143 +549,755 $13.50 549,755 12 Feb 2024 Common Stock 549,755 $0.001000 See Footnote F1, F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These securities are held directly by RA Capital Healthcare Fund, L.P. (the "Fund").
F2 RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
F3 These securities are held directly by the Nexus Fund III.
F4 The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. The Fund may not exercise the Pre-Funded Warrants to the extent that, following exercise, the Fund, together with its affiliates and other attribution parties, would own more than 9.99% of the Common Stock outstanding.

Remarks:

Derek DiRocco, a Partner of the Adviser, serves on the Issuer's board of directors.